A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
UCB Biopharma SRL
Study ID
NCT04718896
Phase
PHASE2
Status
Completed

Conditions

  • Moderate to Severe Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
12 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • bimekizumab — DRUG
    Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

Study Details

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Key Dates

Start date
Apr 6, 2021
Status verified
Apr 2026
Primary completion
Mar 12, 2025
Completion
Mar 12, 2025

Study Design

Enrollment
41 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab Dose A
    Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
  • Experimental: Bimekizumab Dose B
    Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.

Primary Outcome Measure

Plasma Concentration of Bimekizumab at Week 0 [ Time Frame: Baseline (Week 0) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Ps0020 50344IndianapolisIndiana46250-
Ps0020 50359CypressTexas77433-

Related coverage on Hipa.ai

Find similar trials in Indianapolis, IN

By research site
Ps0020 50344· Indianapolis, INPs0020 50359· Cypress, TX

Related Studies